NASDAQ · SMTI
Healthcare · Medical - Instruments & Supplies
$32.17
Up+$0.31 (+0.95%)
Updated Nov 4, 2026, 6:49 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SMTI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SMTI closed at $32.17 after 21 trading sessions, down 8.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $32.13 | $32.415 | $29.045 | $32.17 | 75.23K |
| Nov 2, 2026 | $32.94 | $32.94 | $32.01 | $32.07 | 103.57K |
| Oct 30, 2026 | $32.76 | $33.19 | $32.66 | $32.83 | 97.2K |
| Oct 29, 2026 | $33.13 | $33.13 | $32.73 | $32.915 | 35.14K |
| Oct 28, 2026 | $32.92 | $32.98 | $32.66 | $32.88 | 31.95K |
| Oct 27, 2026 | $33.12 | $33.64 | $32.61 | $32.84 | 75.09K |
| Oct 26, 2026 | $32.33 | $33.02 | $32.33 | $33.02 | 64.41K |
| Oct 23, 2026 | $32.69 | $32.99 | $32.44 | $32.80 | 60.13K |
| Oct 22, 2026 | $32.69 | $32.94 | $32.565 | $32.88 | 62.36K |
| Oct 21, 2026 | $33.16 | $33.16 | $32.60 | $32.77 | 55.95K |
| Oct 20, 2026 | $33.16 | $33.64 | $32.71 | $33.14 | 86.31K |
| Oct 19, 2026 | $32.89 | $33.27 | $32.8301 | $33.14 | 121.81K |
| Oct 16, 2026 | $34.99 | $34.99 | $30.40 | $33.16 | 741.62K |
| Oct 15, 2026 | $35.52 | $35.52 | $35.08 | $35.09 | 164.76K |
| Oct 14, 2026 | $34.90 | $35.12 | $34.90 | $35.12 | 128.5K |
| Oct 13, 2026 | $35.30 | $35.30 | $35.10 | $35.14 | 124.87K |
| Oct 12, 2026 | $35.14 | $35.20 | $35.03 | $35.15 | 156.54K |
| Oct 9, 2026 | $35.05 | $35.09 | $34.92 | $35.07 | 123.98K |
| Oct 8, 2026 | $35.04 | $35.07 | $34.95 | $35.05 | 206.8K |
| Oct 7, 2026 | $34.97 | $35.105 | $34.97 | $35.05 | 136.15K |
| Oct 6, 2026 | $35.09 | $35.09 | $34.95 | $35.00 | 155.59K |
The latest Smart Investors Daily articles mentioning SMTI.
Company
Market Activity
Research & News
SMTI research
Company profile and research snapshot.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 30, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 17, 2026 | Freedom Broker | Buy | — |
| Apr 15, 2026 | Lake Street | Buy | — |
| Jan 26, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 14, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 16, 2026
The Federal Trade Commission issued a Second Request on Friday, seeking additional documents and information from both companies for the merger.
Benzinga · Aug 11, 2026
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $0.02 by 350 percent. This is a 78.26 percent increase over losses of $(0.23) per share from the
Yahoo · Aug 8, 2026
Surgical revenue grew 15% as wound care stabilized ahead of $350M Sanara deal.
Yahoo · Jul 30, 2026
Moby summary of MiMedx Group, Inc.'s Q2 2026 earnings call
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SMTI.
